Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events

A triple-negative breast cancer patient had no hereditary BRCA1, BRCA2, or TP53 risk variants. After exhaustion of standard treatments, she underwent experimental treatments and whole-exome sequencing of tumor, blood, and a metastasis. Well-tolerated experimental bortezomib monotherapy was administe...

Descripción completa

Detalles Bibliográficos
Autores principales: Meißner, Tobias, Mark, Adam, Williams, Casey, Berdel, Wolfgang E., Wiebe, Stephanie, Kerkhoff, Andrea, Wardelmann, Eva, Gaiser, Timo, Müller-Tidow, Carsten, Rosenstiel, Philip, Arnold, Norbert, Leyland-Jones, Brian, Franke, Andre, Stanulla, Martin, Forster, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495034/
https://www.ncbi.nlm.nih.gov/pubmed/28679691
http://dx.doi.org/10.1101/mcs.a001677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495034/
https://www.ncbi.nlm.nih.gov/pubmed/28679691
http://dx.doi.org/10.1101/mcs.a001677

Ejemplares similares